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Abstract 
This study aimed to determine the porcine circovirus type 2 (PCV2) serological and virological dynamics in piglets 
vaccinated at different ages in a PCV2 subclinical infection (PCV2‑SI) scenario. Six hundred and forty‑four 2 week‑
old healthy piglets were selected and distributed into four treatment groups: vaccination at 3, 6 or 10 weeks of age 
(3W‑VAC, 6W‑VAC and 10W‑VAC groups, respectively) and unvaccinated pigs (NON‑VAC group). Blood (n = 112 pigs) 
and oral fluid (OF) (n = 40 pens) samples were taken throughout the study to assess PCV2 load, humoral immunity 
and viral genotyping. Percentage of PCV2‑DNA positive sera mainly raised by 10 weeks of age, being maximum 
at 14 weeks of age, and then started to decrease at 18 and 25 weeks of age. Specifically, PCV2 vaccination at 3 or 
6 weeks of age yielded similar results, since they produced an earlier seroconversion and reduced, at different sam‑
pling points, the proportion of viremic animals in comparison to the unvaccinated group. In contrast, PCV2 vaccina‑
tion at 10 weeks of age only achieved such reduction at 25 weeks of age; in this case, vaccination coincided with the 
increase of the percentage of viremic pigs in the population. Both serological techniques used in sera and OF offered 
similar results with a high and statistically significant correlation. In contrast, a higher percentage of PCV2 DNA positiv‑
ity was detected in OF in comparison with sera. In conclusion, under the present study conditions, the optimal time 
for PCV2 piglet vaccination was at either 3 or 6 weeks of age.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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Introduction
Porcine circovirus type 2 (PCV2) is one of the most 
prevalent viruses that cause great economic losses to the 
worldwide pig industry [1]. This virus has an ubiquitous 
nature in the pig population and is the causative agent of 
a number of clinical and subclinical conditions named 
Porcine circovirus diseases (PCVDs) [2].
Efficacy of PCV2 commercial vaccines has been widely 
demonstrated under field conditions. Major effects have 
been seen on the reduction of the impact of PCV2 sys-
temic disease (PCV2-SD), improvement of production 
parameters, decrease of co-infections, and reduction of 
PCV2 viremia and shedding [3]. Indeed, the wide and 
constant use of such vaccines in PCV2-SD scenarios 
has led, in most farms, to a PCV2 subclinical infection 
(PCV2-SI) scenario [4]. Moreover, most of the pigs from 
PCV2-SD affected farms but not displaying this condi-
tion also suffer from a PCV2-SI. Furthermore, vaccina-
tion against PCV2 has been shown to be economically 
worthy even in PCV2-SI scenarios [5–8].
The most common age of piglet vaccination against 
PCV2 is at 3–4 weeks of age (around weaning). However, 
when a sow and piglet vaccination strategy is planned, 
a delayed piglet vaccination should be considered in 
order to achieve higher vaccine efficacy [9]. Under no 
vaccinated sow scenario, little information is available 
whether the 3–4  week vaccination-age offers the best 
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profit. Although PCV2 vaccines are routinely used in 
most of the worldwide porcine production systems, peer-
reviewed studies comparing the efficacy of PCV2 vac-
cination at different ages are scarce in experimental [10, 
11] and, particularly, under field conditions [12].
Serum is the most commonly used sample to assess 
PCV2 antibody and genome detection [2]. However, 
blood sampling is an individual and invasive method. 
Oral fluid (OF) is an economic and easy-to-take sample 
for detecting antibodies and pathogens in a pig popula-
tion [13–15]. This fact allows a more frequent herd moni-
toring and a greater representativeness of the animal 
group. During last years, PCV2 dynamics after natural 
[16, 17] or experimental [18] infections has been effi-
ciently monitored by OF samples, using both enzyme-
linked immunosorbent assay (ELISA) and polymerase 
chain reaction (PCR) techniques. However, information 
regarding PCV2 assessment in terms of viral load and 
antibody levels in OF after immunization is limited [19].
The objectives of the present study were: (a) to deter-
mine the optimal time for PCV2 vaccination, in terms of 
serological and virological parameters, in pigs vaccinated 
at 3, 6 or 10  weeks of age in a PCV2-SI scenario under 
common PCV2 circulation timings, and (b) to expand 




The study was conducted in a conventional pig farm, 
located in Catalonia (Spain). In order to assess PCV2 
infection status before the start of the study, a cross-
sectional seroprofiling was performed including 10 pigs 
per batch of 6 age groups (3, 7, 11, 15, 19 and 23 weeks 
of age). Blood samples were processed by standard PCR 
[20] and ELISA (Ingezim Circo IgG 11.PCV.K1®, Inge-
nasa, Madrid, Spain) to detect viral nucleic acid and anti-
bodies (IgGs), respectively. PCV2 genome was detected 
in 50, 30, 20 and 10% of the sampled pigs at 11, 15, 19 
and 23 weeks of age, respectively. All the 3 and 7 weeks 
tested samples were negative by PCR. Seroconversion 
was detected from the 11th week of age onwards. There-
fore, as no PCVDs clinical signs were evident in the farm, 
PCV2-SI was confirmed.
This farm was a two-site herd with 800 sows with all-
in/all-out management and 4-week batch farrowing sys-
tem. PCV2 vaccination in sows and piglets had never 
been applied in the studied herd. Sows were routinely 
vaccinated against porcine reproductive and respira-
tory syndrome virus (PRRSV), Aujeszky’s disease virus, 
Swine influenza virus, porcine parvovirus, Erysipelo-
thrix rhusiopathiae, Escherichia coli and Clostridium 
perfringens. Piglets were vaccinated against Mycoplasma 
hyopneumoniae 3  days pre-weaning. Weaning was per-
formed at 3 weeks of age and pigs were moved to fatten-
ing units at 10  weeks of age. Moreover, no signs of any 
major pig diseases were present and herd immunity sta-
tus against PRRSV was determined as “positive-stable” 
(II-A) according to the previously described classification 
[21].
Study design
Six-hundred and forty-four 2 week-old healthy crossbred 
piglets were selected in one single farrowing batch. These 
piglets came from 59 PCV2 non-vaccinated sows with 
low number of weak and cross-fostered piglets in their 
litters. Piglets were individually identified (ear-tagged), 
bled and their gender was recorded. Blood samples were 
tested by ELISA (Ingezim Circo IgG 11.PCV.K1®). Cross-
fostered piglets were not included in the trial. At 3 weeks 
of age, animals were randomly allocated in four treat-
ment groups (Table 1). Groups were randomized accord-
ing to PCV2 ELISA S/P values, sex and litter. Animals 
from different treatment groups were housed in different 
pens (32 pens in nursery and 56 pens in fattening units) 
following a chessboard pattern. Pigs were vaccinated by 
intramuscular injection with 0.5  mL (single dose) of a 
commercial inactivated PCV2 vaccine (CIRCOVAC®, 
Merial SAS, Lyon, France) at either 3, 6 or 10  weeks of 
age (3W-VAC, 6W-VAC and 10W-VAC groups, respec-
tively), and another group of pigs was kept unvaccinated 
(NON-VAC group).
Among all animals included in the study, 28 animals 
per group (14 males and 14 females) with a medium anti-
body titre (ranging from 0.07 to 1.24 ELISA S/P values at 
2 weeks of age) and equally distributed in all pens (2 or 4 
piglets per pen in nursery and 2 piglets per pen in fatten-
ing units) were randomly selected to be bled. From these 
animals, a blood sample was taken at 6, 10, 14, 18 and 
25 weeks of age. Whole blood samples were allowed clot-
ting, and centrifuged at 3200 rpm during 20 min at 4 °C. 
All sera were aliquoted and stored at −20 °C until testing.
Oral fluid samples were collected from a representa-
tive number of pens (24 nursery and 40 fattening pens) 
located at the entrance, middle and final area of the nurs-
ery and fattening units. OF were taken simultaneously to 
blood collection by suspending a non-treated, 3-strand, 
100% cotton rope in each pen for 30 min [22]. Each rope 
was manually squeezed inside a single-use plastic bag for 
OF extraction; then, the corner of the bag was cut and 
the sample was poured into a sterile tube. To avoid cross-
contaminations, all materials (bag, globes, tube) were 
changed or disinfected (scissors) between pens. Once in 
the laboratory, samples were centrifuged at 1000×g dur-
ing 10 min at 4 °C for clearing the sample [14]; then, the 
supernatant was aliquoted and frozen at −80 °C until use.
Page 3 of 11Oliver‑Ferrando et al. Vet Res  (2016) 47:121 
From 2 to 25 weeks of age (at each vaccination or bleed-
ing point), all pigs included in the study were monitored 
for clinical signs and mortality. Animals with major pathol-
ogies (hernia, lameness, injuries, etc.) were excluded from 
the study. Housing conditions, feeding system, feed char-
acteristics and health management remained consistent 
along the course of the trial, and were the same among all 
experimental groups. The present study was approved by 
the Ethics Committee for Animal Experimentation from 
the Universitat Autònoma de Barcelona and the Animal 
Experimentation Commission from the local government 
(Dpt. de Medi Ambient i Habitatge from the Generalitat de 
Catalunya; Reference 5796).
DNA extraction and real‑time quantitative PCR in serum 
and OF samples
DNA was extracted from 200 µL of serum or 300 µL of 
OF samples, by using the MagMAX™ Pathogen RNA/
DNA Kit (Applied Biosystems) following the manufac-
turer’s instructions. The DNA obtained was suspended in 
90 µL of elution solution.
To quantify the PCV2 DNA in serum and OF samples, 
a real-time qPCR assay (LSI VetMAX™ Porcine Cir-
covirus Type 2 Quantification, Life Technologies) was 
performed. Each extraction and qPCR plate included 
negative controls (diethylpyrocarbonate (DEPC)-treated 
water) and each sample reaction had an internal positive 
control (IPC) to monitor DNA extraction and amplifica-
tion procedures. Viral concentrations were expressed as 
the mean log10 PCV2 genome copies/mL. Area under 
the curve (AUC) of viral load in serum samples from 2 to 
25 weeks of age was calculated according to the trapezoi-
dal method as previously described [23].
Serology
Indirect ELISA for detecting anti‑PCV2 IgG antibodies 
in serum samples
All serum samples were tested by the Ingezim Circo 
IgG 11.PCV.K1® assay. The optical density (OD) was 
measured at 450  nm by the PowerWave XS reader 
(BioTek). Mean positive cut-off was established at 0.3 
OD (±SD) following the kit’s instructions (positive cut-
off = OD of negative control +0.25). ELISA results were 
expressed as mean S/P ratio (OD of sample/OD of posi-
tive control for each ELISA plate).
Semi‑quantitative ELISA for detecting anti‑PCV2 antibodies 
in OF samples
All OF samples were processed by the SERELISA® PCV2 
Ab Mono Blocking kit (Synbiotics, Lyon, France) with 
some modifications (protocol used at Labocea, Ploufra-
gan—personal communication). The analysis of the sam-
ples by this technique led to a semi-quantitative result 
expressed as 1 (+), 2 (++), 3 (+++) or 4 (++++).
Viral neutralization test (VNT)
The ability to neutralize PCV2 was assessed by VNT in 14 
randomly selected serum samples per group (half of col-
lected serum samples). This assay was performed as previ-
ously described [24], with the following modifications: (1) 
serum was tested in fourfold dilutions (from 1:4 to 1:4096) 
using supplemented DMEM (Dulbecco’s Modified Eagle 
Medium) in 96-well plates (plates were read using a micro-
scope at 10×  magnifications), and (2) number of PCV2 
infected cells (nuclear and/or cytoplasmic staining) per well 
in each sample replica was counted. Percentage of virus 
neutralization (%VN) at each serum dilution was calcu-
lated as follows:  % VN =  [1 −  (mean number of infected 
cells of the two replicas of each serum dilution/mean num-
ber of infected cells in negative control wells)] ×100. Then, 
VNT50 (i.e. reciprocal of the last dilution of the serum sam-
ple in which the number of PCV2 infected cells was reduced 
to a 50%) was calculated and designated as the neutralizing 
antibody (NA) titre. Results were expressed as log2 NA titre.
PCV2 amplification and sequencing
With the aim of determining the main PCV2 genotype 
circulating in the farm, the capsid protein gene (ORF2) 
Table 1 Experimental design
a Approx. 23 pigs were allocated in each nursery pen.
b Approx. 11 pigs were allocated in each fattening pen.
c Animals were vaccinated with a single dose (0.5 mL) of CIRCOVAC® (Merial SAS, Lyon, France).
Group Total number 
of pigs
Number of bled pigs Number of pens tested by OF 
samples
Treatment
Nursery unita Fattening unitb 3 weeks of age 6 weeks of age 10 weeks of age
3W‑VAC 161 28 6 10 Vaccinationc – –
6W‑VAC 161 28 6 10 – Vaccinationc –
10W‑VAC 161 28 6 10 – – Vaccinationc
NON‑VAC 161 28 6 10 – – –
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was sequenced from two PCV2 qPCR positive samples 
per treatment group. Amplification was done from nucle-
otide 1050 to 1735 (PCV2 genome; GenBank Acces-
sion Number: AY181948) using primers PCV2all_F (5′ 
GGGTCTTTAAGATTAAATYC 3′) and PCV2all_R (5′ 
ATGACGTATCCAAGGAG 3′). PCR was developed in 
a 25  μL reaction containing 1.25  μL of each mentioned 
primer at 10 pmol/μL, 5 μL of 5 × PCR buffer, 2.5 μL of 
MgCl2 at 25 mM, 0.75 U of Taq DNA polymerase, 1 μL of 
dNTP stock solution at 5 mM, 11.35 μL of DEPC-treated 
water and 2.5 μL of extracted DNA. The PCR was started 
with an initial denaturation step of 5  min at 94  °C. The 
temperature profile of the following 40 cycles consisted 
of 30 s at 95 °C for denaturation, 30 s at 53 °C for primer 
annealing and 40 s at 72 °C for elongation. The reaction 
was terminated by a final elongation step of 7  min at 
72 °C. Amplified PCR product was run in an electropho-
resis gel with 1.8% agarose. The band was purified using 
NucleoSpin Gel and PCR Clean-up kit (Macherey–Nagel, 
GmbH & Co. KG, Germany) according to the manufac-
turer’s instruction. Sequencing reactions were performed 
with BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA, USA) and analysed 
using a 3130 × l Genetic Analyser (Applied Biosystems).
PCV2 capsid protein (ORF2) phylogenetic and sequence 
analysis
Nucleotide sequences of the PCV2 capsid protein were 
analysed using Bioedit v7.0.9.0 [25]. Sequences were 
aligned using the Clustal W multiple alignment method 
included in the Bioedit package [26]. Fifteen strains of 
different PCV2 genotypes retrieved from the GenBank 
database were included in the comparison. The phylo-
genetic tree was constructed according to the Neighbor-
Joining method with 1000 bootstrap replicates using 
MEGA version 4 [27].
Statistical analyses
Animal mortality and exclusion rates between groups 
were compared using the likelihood ratio test. General-
ized linear mixed models for longitudinal binary data 
were performed to analyse the evolution between groups 
for PCV2 qPCR (positive/negative) values in pigs (serum 
samples) and pens (OF samples). Treatment group, sam-
pling point and their interaction were considered as fixed 
effects, and piglet and pen as random effects. Whenever 
differences between groups were detected, they were fur-
ther evaluated by pairwise comparisons. p-values were 
corrected using Tukey’s method. Generalized linear 
mixed models were applied for longitudinal continuous 
data such as mean log10 PCV2 copies/mL in qPCR posi-
tive serum and OF samples, mean ELISA S/P IgG values 
in sera, mean ELISA semi-quantitative values in OF and 
log2 NA titre in sera. The comparison of PCV2 AUC load 
in serum samples between groups was analysed by a non-
parametric test (Kruskall-Wallis statistic). Pearson’s cor-
relation coefficient was used to assess the relationship 
between serum and OF results (ELISA and qPCR), as 
well as between ELISA values from both serum and OF 
samples in comparison to NA titres in serum samples. 
Statistical analyses were carried out using SAS v9.4, SAS 




No clinical signs related to PCV2-SD were observed dur-
ing the course of the study. No statistically significant dif-
ferences in terms of mortality rate and animal exclusion 
(ranging from 2.5 to 7.5% in all groups) were observed 
among treatment groups during the whole experimental 
period (data not shown).
Quantification of PCV2 DNA
Serum samples
While very few pigs were qPCR positive at 3 and 6 weeks 
of age, the percentage of PCV2-DNA positive pig sera 
raised at 10 weeks of age, was maximum at 14 weeks of 
age and then started to decrease by 18 and 25 weeks of 
age. Particularly, animals from 3W-VAC to 6W-VAC 
groups had a significantly lower (p < 0.05) percentage of 
viremic animals (Figure 1A) compared to the NON-VAC 
group at 14, 18 and 25 weeks of age (in 3W-VAC group) 
and at 14 and 18  weeks of age (in 6W-VAC group). In 
contrast, the 10W-VAC group showed a higher percent-
age of viremic pigs than 3W-VAC and 6W-VAC groups 
at 10, 14 and 18 weeks of age (only significantly different 
at 18 weeks of age), but lower than that of control group 
at 14, 18 and 25 weeks of age (only significant at 25 weeks 
of age). At the peak of infection (14  weeks of age), the 
3W-VAC group showed a significantly lower (p  <  0.05) 
PCV2 load (Figure  1B) than the NON-VAC group. The 
6W-VAC and 10W-VAC groups also showed the same 
trend with lower viral loads than the NON-VAC group 
but these differences were not statistically significant. 
The 3W-VAC and 6W-VAC groups experienced a signifi-
cantly lower AUC of viral load than the NON-VAC group 
(p < 0.05) (Table 2). However, PCV2 AUC of 10W-VAC 
group was only numerically lower than that of the NON-
VAC group.
OF samples
At 3 weeks of age, OF collection was not possible since 
piglets did not chew the ropes. Percentage of PCV2 
qPCR positive pens (Figure 2A) was high at all sampling 
points and no statistically significant differences among 
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treatment groups were observed. At the peak of infec-
tion (14 weeks of age), 100% of positivity was observed in 
all groups. At this time point, viral load (Figure 2B) was 
numerically lower in all the vaccinated groups compared 
to the control group.
Virological results obtained from serum and OF sam-
ples showed positive but non-significant correlations: 
percentage of PCV2 qPCR positive samples (r  =  0.86; 
p = 0.06) and viral load (r = 0.76; p = 0.13).
Serology
Anti‑PCV2 IgG antibody levels in serum samples
The course of antibodies against PCV2 in the four treat-
ment groups is shown in Figure 3. From 2 to 6 weeks of 
age, all groups presented a decrease of ELISA S/P values 
and no differences between groups were observed. At 
10 weeks of age, 3W-VAC and 6W-VAC groups showed 
significantly higher (p < 0.05) S/P values than 10W-VAC 
and NON-VAC groups. The 10W-VAC group serocon-
verted by 14  weeks of age, reaching significantly higher 
antibody levels at 18 weeks of age compared to the other 
groups. The NON-VAC group seroconverted by 14 to 
18 weeks of age. From this time point onwards, S/P val-
ues of the vaccinated groups began to decrease whereas 
the ones of the control group remained stable.
Anti‑PCV2 antibody levels in OF samples
Mean semi-quantitative antibody values in OF are sum-
marized in Figure  4. At 10  weeks of age, the 3W-VAC 
group displayed a statistically significant increase of anti-
body response compared to all other groups. At the same 
time point, the other groups experienced a decrease of 
Figure 1 Percentage of PCV2 qPCR positive pigs (A) and mean 
viral load (±SD) of qPCR positive serum samples (B). Differ‑
ent letters in superscript mean statistically significant differences 
(p < 0.05) among experimental groups at each sampling point.
Table 2 Area under the curve (AUC) of PCV2 load (log10 
PCV2 copies/mL) in serum samples from 2 to 25 weeks of 
age
Different letters in superscript mean statistically significant differences (p < 0.05) 
among experimental groups.
Group Mean AUC of viral load
3W-VAC 3.25a (Min. = 0.00/Max. = 6.48)
6W-VAC 3.79a (Min. = 0.00/Max. = 7.41)
10W-VAC 4.92ab (Min. = 0.00/Max. = 7.75)
NON-VAC 5.65b (Min. = 0.00/Max. = 7.90)
Figure 2 Percentage of PCV2 qPCR positive pens (A) and mean 
viral load (±SD) of qPCR positive oral fluids samples (B).  Dif‑
ferent letters in superscript mean statistically significant differences 
(p < 0.05) among experimental groups at each sampling point.
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antibody levels, being the ones of the 6W-VAC group sig-
nificantly higher than the ones of the NON-VAC group. 
Four weeks later, i.e. at the peak of infection, all vaccinated 
groups showed significantly higher antibody values than 
the NON-VAC group. From 18  weeks of age onwards, 
antibody levels from all groups remained high and no sig-
nificant differences were observed between them.
A high and statistically significant correlation (r = 0.95, 
p  =  0.015) between serum and OF ELISA results was 
observed.
Figure 3 PCV2 ELISA S/P results (mean ± SD) in serum samples. Different letters in superscript mean statistically significant differences 
(p < 0.05) among experimental groups at each sampling point.
Figure 4 PCV2 ELISA semi-quantitative values (mean ± SD) in oral fluid samples. Different letters in superscript mean statistically signifi‑
cant differences (p < 0.05) among experimental groups at each sampling point.
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Neutralizing antibody titres in serum samples
Mean NA titres (±  SD) dynamics for each treatment 
group is depicted in Figure 5. From 2 to 6 weeks of age, 
all groups showed a decrease of NA titres and no differ-
ences between groups were observed. Subsequently, pigs 
from groups 3W-VAC and 6W-VAC had significantly 
higher NA levels compared to the 10W-VAC (at 10 weeks 
of age) and NON-VAC (at 10 and 14 weeks of age) pigs. 
In the 10W-VAC group, the increase of NA titres was 
observed 4 weeks after vaccination, i.e. 14 weeks of age, 
being significantly higher than the ones in NON-VAC 
pigs. The NA response for animals of the NON-VAC 
group was detected at 14  weeks of age, reaching maxi-
mum levels at 18 weeks of age. After this sampling point, 
NA levels from all groups began to decrease.
High and statistically significant correlations were 
found between NA titres tested in serum samples in 
comparison to ELISA values detected in serum (r = 0.97, 
p = 0.001) and OF (r = 0.90, p = 0.038) samples.
PCV2 genotyping
A Neighbor-Joining phylogenetic tree including the rela-
tionships among the PCV2 isolates sequenced in this 
study (two per experimental group) and reference strains 
is represented in Figure 6. All serum samples sequenced 
(GenBank accession numbers: KX670778–KX670785) 
were genetically closely related and clustered within 
PCV2a genotype.
Discussion
Several studies have shown that PCV2 piglet vaccination 
at weaning age (3–4 weeks of age) is effective regardless 
of the PCVD farm status (PCV2-SD or PCV2-SI) and 
the brand of commercial vaccine used [3]. Vaccination 
schedules at earlier ages with one single dose are rarely 
applied, since high levels of maternally derived antibod-
ies (MDA) at the vaccination time may cause a lower 
humoral  immune response (interference with the sero-
conversion) elicited by the vaccine [6, 11, 28, 29] and may 
eventually jeopardize the efficacy of vaccination [8, 30].
In the peer-reviewed literature, little information does 
exist on PCV2 vaccine efficacy obtained by compar-
ing vaccination of piglets (coming from non-vaccinated 
sows) at different postweaning ages [11, 12]. In the pre-
sent study, PCV2 vaccination in piglets at 3 or 6  weeks 
of age yielded similar virological and serological results, 
producing a relatively early humoral immune response 
and reducing the proportion of viremic animals in com-
parison to the unvaccinated group. These results are in 
accordance with two previously published trials, where 
no statistically significant differences in terms of PCV2 
viremia and/or humoral and cellular immunity were 
found between pigs vaccinated at 3 and 6  weeks of age 
[12], and at 3–7  weeks of age [11]. In addition, it has 
also been demonstrated that vaccination of older ani-
mals (8.5 weeks of age) with a subunit vaccine and under 
a PCV2-SD scenario resulted in a significantly lower 
Figure 5 PCV2 NA titres (mean ± SD) in serum samples. Different letters in superscript mean statistically significant differences (p < 0.05) 
among experimental groups at each sampling point.
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mortality in vaccinates than in controls [31]. Although 
in this latter study, serological and virological param-
eters from pigs vaccinated at this time point were not 
tested, the vaccination took place, most probably, when 
a proportion of pigs were already infected. As far as the 
authors knowledge, no more information is available on 
the efficacy of piglet vaccination at older ages. Thus, the 
present study represents the first time comparing the use 
of vaccination at 10 weeks of age (entering to the fatten-
ing facilities) with earlier ages. Under the conditions of 
the present farm trial, PCV2 vaccination at 10 weeks of 
age was probably done too late for an optimal perfor-
mance as it coincided with the increase of the percentage 
of viremic pigs in all the treatment groups. Under field 
conditions, PCV2 viremia usually starts at the end of 
the nursery or at the beginning of fattening periods, 
although it is variable depending on the farm and even 
the production batch [32]. In the present farm scenario, 
vaccination at 10  weeks of age was able to numerically 
reduce the percentage of viremic animals at 14 (peak of 
infection), 18 and 25 weeks of age in comparison with the 
control group, being statistically significant at the latter 
time point. This evidence is in agreement with a previ-
ous experimental trial [33], showing that vaccination of 
PCV2 viremic and seropositive piglets leads to a humoral 















































Figure 6 Neighbor-Joining phylogenetic tree with 1000 bootstrap replicates showing the relationships among the nucleotide 
sequences of the PCV2 capsid protein. PCV2 strains sequenced in this study from 3W‑VAC (*), 6W‑VAC (**), 10W‑VAC (***) and NON‑VAC (****) 
groups are compared to PCV2 types a, b, c and d strains. Horizontal branches indicate the sequence distance (number of base differences per site).
Page 9 of 11Oliver‑Ferrando et al. Vet Res  (2016) 47:121 
viremia. Therefore, although not optimal, vaccination of 
viremic pigs seems to exert a positive effect compared to 
viremic, non-vaccinated ones.
The current work further demonstrated the ability of an 
inactivated vaccine to produce a NA response after piglet 
immunization at different ages. This response led to a sig-
nificantly greater protection (in terms of PCV2 viremia) 
of groups vaccinated before natural infection compared 
to the group vaccinated after the onset of infection, i.e. 
at 10  weeks of age, and the control group. The inverse 
dynamics between NA titres and PCV2 load in serum 
found in the present study had previously been described 
[24, 34, 35]. In addition, an immune response analysis 
of the four major vaccines available on the market was 
performed in a recent study [36], confirming the ability 
of the inactivated vaccine used in this study to induce a 
NA response after vaccination, producing higher NA lev-
els than the ones from subunit vaccines. Moreover, in the 
current work, high and statistically significant correla-
tions were found between ELISA values from both serum 
and OF samples in comparison to NA titres in sera. This 
finding suggests that antibody levels tested by the used 
ELISA kits might be used as potential predictor of NA 
titres.
Both serological techniques used in serum and OF sam-
ples offered similar results with a high and statistically 
significant correlation among them. These results would 
suggest that OF samples can be an alternative to serum 
for studying PCV2 antibody dynamics. This outcome is 
in agreement with a reported trial [16] in which positive 
correlation between OF and pooled sera in terms of anti-
body detection was found. In contrast, a higher PCV2 
qPCR positivity was detected in the present study from 
OF in comparison with sera at all sampling points, and 
no significant differences between treatment groups were 
observed by using OF. Moreover, PCV2 circulation was 
detected earlier in OF (from 6  weeks of age) compared 
to sera (from 10 weeks of age) in all groups of pigs. These 
findings are in accordance with a previous study [16] and 
support the fact that the starting time of PCV2 circula-
tion and viremia might be different. However, in terms of 
PCV2 load, whereas similar levels of PCV2 DNA in OF 
and serum samples with a significant correlation were 
described [16], higher mean viral loads in OF (over one 
logarithm) with no significant correlation to PCV2 loads 
in sera were detected in the current study at infection 
peak (14 weeks of age). The higher qPCR positivity per-
centages and PCV2 load in OF compared to sera may be 
explained by a number of reasons. First, serum samples 
were obtained from only two or four pigs per pen, but OF 
sample was a collective sample representing around 23 or 
11 pigs per nursery or fattening pen, respectively. There-
fore, there is a reasonable probability that some viremic/
shedder animals were not bled or alternatively that the 
bled subjects were not the ones with the highest viral 
loads. Second, since PCV2 replicates firstly in the tonsil 
[37, 38], it might be probably detected at an earlier stage 
and with a greater concentration in OF with regards to 
sera as has been previously suggested [16]. Finally, PCV2 
is an endemic and very stable virus [39] that might be 
ever-present in pens [40]. In fact, it has been demon-
strated that PCV2 subclinically infected pigs may excrete 
medium to high viral loads in faeces [41, 42]. Therefore, it 
should be taken into account that ropes might be spoiled 
by the traces of faeces present in the mouth/skin of the 
pigs.
In all sequenced samples (n = 8), PCV2a genotype was 
identified. Although this genotype has a worldwide dis-
tribution [43], the most current prevalent genotype in 
the pig population is PCV2b [1, 44]. Indeed, it has been 
proposed that PCV2b is more prevalent than PCV2a in 
PCV2-SD cases and in vaccinated farms [45]. The PCV2-
SI scenario in the studied farm and the fact that no 
PCVD compatible clinical signs had ever been observed 
before the start of the study (and in consequence, vac-
cination had never been applied before this trial) might 
be related with the detection of PCV2a genotype in the 
farm. The apparent sole presence of PCV2a genotype was 
not enough to produce overt disease in this farm. In fact, 
the speculation that PCV2a might not be as efficient as 
PCV2b to trigger clinically evident disease came from 
the demonstration of a worldwide genotype shift from 
PCV2a to PCV2b coinciding with major outbreaks of 
PCV2-SD around the globe [1].
In conclusion, under the conditions of this study, the 
optimal age for piglet vaccination was at 3 or 6 weeks of 
age, since it was applied when the percentage of viremic 
pigs was minimal, triggering an effective humoral 
immune response before the peak of infection. These 
strategies were able to reduce, at different sampling 
points, the proportion of viremic animals in comparison 
to the unvaccinated group. In contrast, PCV2 vaccina-
tion at 10  weeks of age (coinciding with the increase of 
the percentage of viremic pigs in the population) only 
achieved such reduction at 25  weeks of age. Therefore, 
age at PCV2 vaccination should be adapted according to 
the viral infection dynamics present in the studied farm. 
Moreover, both serological techniques used in sera and 
OF were useful to study PCV2 antibody dynamics. In 
contrast, viral detection in OF might be useful to have 
an idea of the infection dynamics at population level but 
should remain only as a raw indicative method.
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